AI-Lung Cancer Test Volume +216% as bioAffinity Expands to Surveillance

On September 2, 2026, shares of bioAffinity Technologies (NASDAQ: BIAF) rose 47.95% in a single session, one day after the company announced it was advancing the potential use of CyPath Lung for post-treatment surveillance of lung-cancer patients. The jump came just over a week after a 1-for-15 reverse split became effective for trading on August 24, a move intended to restore Nasdaq listing compliance without changing the underlying economics. That combination produced a dramatic percentage swing in a thinly traded stock, with the shares also up 19.48% at the time of the analysis. Behind the price action is a diagnostic company that uses artificial intelligence with flow cytometry to analyze sputum samples for signs associated with lung cancer. The commercial thesis is straightforward: if physicians adopt CyPath Lung as a non-invasive tool for high-risk patients with pulmonary nodules, it could reduce unnecessary invasive procedures and create a recurring diagnostic revenue stream. Second-quarter test volume increased 216% year over year, a notable growth rate but one that comes from a very small base. A published clinical study reported 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value among high-risk patients with pulmonary nodules smaller than 20 millimeters. Those numbers are compelling on paper, particularly the 99% negative predictive value, which suggests that a negative CyPath Lung result could help rule out cancer in a population that otherwise might face repeated imaging or invasive biopsy. The expansion into post-treatment surveillance is the key strategic shift. If patients need monitoring after treatment rather than only an initial diagnostic decision, the total addressable testing population expands substantially. However, the financial base is extremely small. bioAffinity posted a $3.4 million net loss in the second quarter, an improvement from a $4.1 million loss a year earlier, but still a significant cash drain. Cash fell to $2.4 million at quarter-end, down from $6.4 million at December 31. A June offering produced $3.2 million of gross proceeds and about $2.6 million of estimated net proceeds, and the company closed another $4 million gross private placement on August 14. That capital supports commercialization, but the pre-funded and other warrants created additional dilution risk for existing shareholders. Hedge-fund participation remains minimal: Insider Monkey tracked two funds holding bioAffinity Technologies in both Q2 and Q1, meaning small transactions can distort percentage comparisons. Short positioning also required a split adjustment, with the August 14 settlement showing 195,685 pre-split shares short, down from 327,035. The reverse split itself did not change the company's underlying economics, but it reduced the share count and can amplify both upward and downward moves, especially with thin institutional ownership. What would have to go right for the stock to build on this move? First, CyPath Lung must demonstrate real-world clinical utility in the surveillance setting, not just in the original high-risk nodule protocol. Second, reimbursement and payer coverage must expand enough to support commercial adoption among pulmonologists and oncologists. Third, test volume growth must continue at a pace that eventually closes the gap between revenue and operating expenses. Fourth, the company must manage its cash runway and dilution overhang without further eroding shareholder value. The 47.95% jump may reflect speculative repositioning after a reverse split rather than a fundamental revaluation. Investors should watch upcoming quarters for test volume, cash burn, gross margins, any payer coverage announcements, and evidence that the surveillance indication translates into durable revenue. The central question is whether bioAffinity can convert its clinical accuracy into sustainable commercial growth before its limited cash reserves run out.